Tango Therapeutics banks $60M to push synthetic lethality drug into the clinic
Many cancer patients have benefited from targeted therapies that switch off cancer-driving oncogenes, but others, whose disease is driven by the loss of tumor-suppressing genes, have missed out on such treatments. Tango Therapeutics is working on a pipeline of drugs to change that, raising $60 million to fuel its efforts.